| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/06/2006 | EP1697382A2 Rifamycin analogs and uses thereof |
| 09/06/2006 | EP1697381A1 Mitotic kinesin inhibitors |
| 09/06/2006 | EP1697379A1 Spirocyclic cyclohexane derivatives |
| 09/06/2006 | EP1697378A2 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| 09/06/2006 | EP1697377A1 Polycyclic agents for the treatment of respiratory syncytial virus infections |
| 09/06/2006 | EP1697375A2 Heterocyclic protein kinase inhibitors and uses thereof |
| 09/06/2006 | EP1697374A1 Crf receptor antagonists and methods relating thereto |
| 09/06/2006 | EP1697371A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 09/06/2006 | EP1697370A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 09/06/2006 | EP1697369A1 Crf receptor antagonists and methods relating thereto |
| 09/06/2006 | EP1697363A2 Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| 09/06/2006 | EP1697362A1 Crf receptor antagonists and methods relating thereto |
| 09/06/2006 | EP1697361A1 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| 09/06/2006 | EP1697360A1 Novel crystalline forms of 2, 3 dimethyl-8- (2, 6-dimethylbenzylamino) -n-hydroxyethyl-imidazo 1, 2-a pyridine-6-carboxamide mesylate salt. |
| 09/06/2006 | EP1697359A1 Muscarinic agonists as therapeutic compounds |
| 09/06/2006 | EP1697357A2 Tricyclic benzimidazoles |
| 09/06/2006 | EP1697356A1 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| 09/06/2006 | EP1697355A2 Amidino compounds as cysteine protease inhibitors |
| 09/06/2006 | EP1697354A1 Isothiazole dioxides as cxc- and cc- chemokine receptor ligands |
| 09/06/2006 | EP1697353A2 Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors |
| 09/06/2006 | EP1697352A2 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| 09/06/2006 | EP1697351A1 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| 09/06/2006 | EP1697350A1 Tricyclic steroid hormone nuclear receptor modulators |
| 09/06/2006 | EP1697349A1 Doxepin analogs and methods of use thereof |
| 09/06/2006 | EP1697348A1 Hiv protease inhibiting compounds |
| 09/06/2006 | EP1697347A1 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratiory syncytial virus replication |
| 09/06/2006 | EP1697346A1 Crystalline form of 2-{ 4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl} -2-oxoethanol |
| 09/06/2006 | EP1697345A1 Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication |
| 09/06/2006 | EP1697344A2 Hiv protease inhibiting compounds |
| 09/06/2006 | EP1697343A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| 09/06/2006 | EP1697342A2 Dipeptidyl peptidase inhibitors |
| 09/06/2006 | EP1697336A2 Aroylfuranes and aroylthiophenes suitable for the treatment of cancer |
| 09/06/2006 | EP1697334A1 Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
| 09/06/2006 | EP1697333A1 (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| 09/06/2006 | EP1697332A1 Benzo'1,4 ! diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof |
| 09/06/2006 | EP1697331A2 Mitotic kinesin inhibitors |
| 09/06/2006 | EP1697326A1 Crystal form of quinoline compound and process for its production |
| 09/06/2006 | EP1697324A1 Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators |
| 09/06/2006 | EP1697323A1 New 5,6-dihydropyrin-2-one compounds useful as inhibitors of thrombin |
| 09/06/2006 | EP1697322A1 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| 09/06/2006 | EP1697319A1 Pyrrole compounds |
| 09/06/2006 | EP1697318A1 Prolinylarylacetamides |
| 09/06/2006 | EP1697313A2 Processes for the preparation of aminoalkyl phenylcarbamates |
| 09/06/2006 | EP1697312A2 Hydroxamic acid esters and pharmaceutical use thereof |
| 09/06/2006 | EP1697308A2 Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| 09/06/2006 | EP1697306A1 Selective peroxisome proliferator activated receptor modulators |
| 09/06/2006 | EP1697305A1 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists |
| 09/06/2006 | EP1697304A1 Peroxisome proliferator activated receptor modulators |
| 09/06/2006 | EP1697303A1 Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifiying and obtaining the polymorphs thereof |
| 09/06/2006 | EP1697302A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders |
| 09/06/2006 | EP1697050A2 Fiber rich fraction of trigonella foenum-graceumseeds and its use as a pharmaceutical excipient |
| 09/06/2006 | EP1697005A1 Combination of flupirtine and tramadol |
| 09/06/2006 | EP1696961A1 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof |
| 09/06/2006 | EP1696959A2 Melatonin combination therapy for improving sleep quality |
| 09/06/2006 | EP1696958A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 09/06/2006 | EP1696954A1 Vaccine composition admixed with an alkylphosphatidylcholine |
| 09/06/2006 | EP1696939A2 Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
| 09/06/2006 | EP1696938A1 Element sulfur as an oral or parental medical product |
| 09/06/2006 | EP1696937A1 Prebiotic combination products |
| 09/06/2006 | EP1696936A2 Cosmetic or pharmaceutical preparations containing nucleic acid sequences forming a superstructure |
| 09/06/2006 | EP1696935A1 Novel derivatives of morphine-6-glucuronide, pharmaceutical compositions containing said derivatives, preparation method thereof and uses of same |
| 09/06/2006 | EP1696934A1 Florfenicol prodrug having improved water solubility |
| 09/06/2006 | EP1696933A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 09/06/2006 | EP1696932A1 Use of treprostinil to improve kidney functions |
| 09/06/2006 | EP1696931A2 Amino substituted diaryl [a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 09/06/2006 | EP1696930A1 Tricyclic 1-((3-indol-3-yl)carbonyl)piperazine derivatives as cannabinoid cb1 receptor agonists |
| 09/06/2006 | EP1696929A2 Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis |
| 09/06/2006 | EP1696928A1 Cdk2 antagonists as short form c-maf transcription factor antagonists for treatment of glaucoma |
| 09/06/2006 | EP1696927A2 Mitotic kinesin inhibitors |
| 09/06/2006 | EP1696926A1 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| 09/06/2006 | EP1696925A2 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 09/06/2006 | EP1696924A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 09/06/2006 | EP1696923A2 Nicotine delivery product and method for producing |
| 09/06/2006 | EP1696922A1 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
| 09/06/2006 | EP1696921A1 Tricyclic imidazopyridines for use as gastric secretion inhibitors |
| 09/06/2006 | EP1696920A2 Compounds and methods for development of ret modulators |
| 09/06/2006 | EP1696919A2 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| 09/06/2006 | EP1696918A2 A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor |
| 09/06/2006 | EP1696917A1 COMBINATION OF (a) N-{5- [4-(4-METHYL-PIPERAZINO-METHYL) -BENZOYLAMIDO] -2METHYLPHENYL]-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF |
| 09/06/2006 | EP1696916A1 Use of metabotropic glutamate receptor 5 (mglur5) antagonists for the treatment of gastrointestinal disorders |
| 09/06/2006 | EP1696915A1 Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| 09/06/2006 | EP1696914A1 3-cyano-quinoline derivatives with antiproliferative activity |
| 09/06/2006 | EP1696913A1 Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| 09/06/2006 | EP1696912A2 Pyrazolopyridines and analogs thereof |
| 09/06/2006 | EP1696911A1 Intranasal compositions |
| 09/06/2006 | EP1696910A1 Compositions and methods for treatment of fibrosis |
| 09/06/2006 | EP1696909A1 Benzothiazole derivatives for the treatment of diabetes |
| 09/06/2006 | EP1696908A1 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof |
| 09/06/2006 | EP1696907A1 Pdk-1/akt signaling inhibitors |
| 09/06/2006 | EP1696906A1 Novel therapeutic use of indolinone derivatives |
| 09/06/2006 | EP1696905A1 Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease |
| 09/06/2006 | EP1696904A1 Use of rotigotine for the treatment or prevention of dopaminergic neurone loss |
| 09/06/2006 | EP1696903A1 Combination of 2,3-dibenzylbutyrolactone and licochalcone-a |
| 09/06/2006 | EP1696902A2 Compositions containing d-tocopherol compound polybasic acid partial esters |
| 09/06/2006 | EP1696901A1 The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases |
| 09/06/2006 | EP1696900A1 Use of treprostinil to treat and prevent ischemic lesions |
| 09/06/2006 | EP1696899A1 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b |
| 09/06/2006 | EP1696898A2 Zn 24 -chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors |
| 09/06/2006 | EP1696897A1 Compositions and methods for treating diabetes |
| 09/06/2006 | EP1696896A2 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |